On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Innovent reports NMPA approval in China for weight management. Approval is jurisdiction- and product-specific.
Dual agonism
Mazdutide combines GLP-1 and glucagon receptor actions in one molecule. Benefits must be demonstrated for that molecule and population. [1]
What the evidence shows
Weight-management trial
A phase 3 placebo-controlled trial in China studied adults with overweight or obesity for 48 weeks. Both tested mazdutide groups achieved greater weight reduction than placebo. [1]
Reading trial eligibility
Participants met the trial’s Chinese BMI and comorbidity criteria. Those definitions and the enrolled population should be considered before comparing percentages with trials conducted elsewhere. [1]
Approval in China
Innovent announced China’s NMPA approval for chronic weight management in June 2025. That announcement does not establish FDA approval or verify a research vial sold elsewhere. [2]
What remains unknown
The cited trial does not settle rare long-term harms or prove equivalence to another dual agonist.
Safety
Tolerability
Gastrointestinal events were the most common adverse events in this trial. Trial averages do not predict which individual will tolerate treatment. [1]
Studied preparation
The study used a subcutaneous clinical-trial formulation. A similarly named research product is not verified by the publication. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is it another name for tirzepatide?
No. Mazdutide includes glucagon-receptor activity; tirzepatide targets GIP and GLP-1 receptors.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight2025 · Primary research · PubMed
- Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight ManagementInnovent · June 2025 · Manufacturer approval announcement
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.